---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-052058"
form_type: "8-K"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T00:11:42.040139+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# aTyr Pharma Q1 2024 update: Phase 3 EFZO-FIT completes enrollment expected in Q2 2024

## Summary
- Cash, cash equivalents, restricted cash and investments totaled $87.7 million as of March 31, 2024.
- Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis enrollment completion expected in Q2 2024.
- Phase 2 EFZO-CONNECT study in systemic sclerosis-associated ILD enrolling at multiple U.S. sites.
- R&D expenses of $13.4 million and G&A expenses of $3.5 million for Q1 2024.
- Collaboration revenue of $0.2 million from Kyorin agreement for drug product material sold.

## SEC filing metadata
- accession: 0000950170-24-052058
- form_type: 8-K
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000095017024052058/0000950170-24-052058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000095017024052058/life-20240502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-052058
- JSON: https://secwatch.observer/filing/0000950170-24-052058.json
- Plain text: https://secwatch.observer/filing/0000950170-24-052058.txt

## Key facts
- Earnings Releases
  aTYR PHARMA INC reported financial results for the three months ended March 31, 2024.
  - Period: the three months ended March 31, 2024
  - Result: reported results
  source text: On May 2, 2024, aTyr Pharma, Inc. issued a press release announcing financial results for the three months ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1339970/000095017024052058/0000950170-24-052058-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.